Cystic Fibrosis Market Trends

Global Cystic Fibrosis Market Overview

The Cystic Fibrosis Market Size was valued at USD 6.01 billion in 2023 and is projected to grow from USD 6.84 Billion in 2024 to USD 20.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.95% during the forecast period (2024 - 2032). Some key market drivers propelling the expansion of cystic fibrosis include rising awareness of this progressive hereditary condition and the expanding use of pharmacological therapy.

In May 2024, Vertex Pharmaceuticals, which heavily relies on a particular product or service for its success, has shown a strong desire to expand and vary its sources of income in the past few years. Vertex is making significant progress towards achieving its aim as numerous patients begin their treatment with Casgevy, the company's gene-editing cell therapy developed in collaboration with CRISPR technology. After receiving clearance from Casgevy for sickle cell disease (SCD) in December and beta thalassemia in the following month, Vertex Pharmaceuticals is currently making significant advancements in activating authorized treatment centers, engaging physicians and patients, and having discussions with payers. In addition to the activation of treatment centers, Vertex also discussed the significant launch component of cell collection during its first-quarter earnings call. By mid-April, cellular samples were obtained from five patients in the three regions where Casgevy is now authorized: the United States, Europe, and the Middle East. Arbuckle praised the milestone as a remarkable achievement, considering the relatively brief period since approval, as well as the intricate and lengthy process patients undergo on Casgevy. According to Vertex's statistics, their drug Casgevy is ranked higher than its competitor Lyfgenia from bluebird bio in terms of FDA approval. Both drugs received permission from the FDA at the same time in December. Bluebird revealed that it had only gathered cells from one patient for its SCD gene treatment.

In January 2024, Clarametyx Biosciences, a company based in the United States, will begin enrolling participants for a Phase Ib/IIa research. The trial aims to investigate the use of CMTX-101 as an additional treatment for people with cystic fibrosis (CF). The Phase Ib/II trial (NCT06159725), funded by the Cystic Fibrosis Foundation, aims to assess the safety of CMTX-101 in individuals with stable cystic fibrosis and chronic infection in the United States. Participants in the clinical trial will be administered CMTX-101 in conjunction with tobramycin for a duration of 28 days. CMTX-101 is a highly precise anti-biofilm agent that improves the sensitivity of antibiotics, potentially leading to a decrease in antibiotic resistance rates. The candidate has antagonistic activity against DNABII protein, causing rapid disruption of biofilms and subsequent release of resident bacteria. This facilitates their elimination through either the human immune system or antibiotic treatment. The Phase Ib stage will be a study where six patients will participate and the dosage will be increased gradually. The trial will be open-label, meaning that both the patients and the researchers will know which treatment is being administered. The dosages will consist of 5 milligrams, 15 milligrams, and 30 milligrams. Richards stated that the registration process for the Phase Ib group has commenced.

Cystic Fibrosis Market Trends

• Growing cases of cystic fibrosis to propel market growth

In all parts of the world, CF is swiftly overtaking other hereditary diseases in terms of prevalence. More than 30,000 people in the United States currently have cystic fibrosis, and it is anticipated that 70,000 people worldwide have this disorder, according to the Cystic Fibrosis Patient Registry. It is also mentioned that the illness is diagnosed in about 1,000 new cases annually. Therefore, it is projected that there will be an increase in demand for the treatment of the condition throughout the course of the projection period due to the rising prevalence of respiratory problems, gastrointestinal problems, and reproductive illnesses in CF patients. The adoption of novel treatment approaches for early detection is also increasing the patient base for improved treatment, which is anticipated to affect the market's growth throughout the anticipated period. Thus, this factor is driving the market CAGR.

Furthermore, cystic fibrosis sufferers are becoming more prevalent worldwide, which has sparked the industry. Pharmacotherapy for cystic fibrosis has led to many advancements in managing this condition, helping the market grow. The industry's rise is also fueled by market trends that are now being used in treating the ailment. This is due to a growing number of candidates for therapeutic care are being produced by important corporations and are currently in the pipeline. As a result, pharmaceutical firms are being pushed to create novel therapies that deal with CFTR protein abnormalities. Additionally, the launch of Lumacaftor/Ivacaftor, a potentiator that improves the quality of life for patients with the disease, also assists in the market's growth.

However, the market is expanding due to the impending introduction of medications for treating CF. During the anticipated period, the market expansion will be aided by introducing medications that target the fault in diseased people's cells. The market expansion is being influenced by the likelihood that this medicine will change many people's lives. The market is also thought to be primarily driven by an increase in the disease's prevalence. This, in turn, is accelerating the introduction of recently developed pipeline medications necessary for the care of critical patients. Additionally, many potential candidates are in the last stages of development and anticipate the market will rise soon. As an illustration, Vertex Pharmaceuticals Incorporated recently reported encouraging findings from their phase III clinical study on inhaled mannitol used to treat mucociliary clearance. The market is also anticipated to grow due to technologically sophisticated devices utilized for various serious situations, such as mucus thinners, airway clearance procedures, and others. Thus, it is anticipated that this aspect will accelerate Cystic Acne market revenue globally.

Cystic Fibrosis Market Segment Insights:

Cystic Fibrosis Treatment Method Insights

The Cystic Fibrosis Market segmentation, based on treatment methods, includes medication and devices. The medication segment held the majority share in 2022 in the Cystic Fibrosis Market data. Growing public awareness of the potential danger posed by cystic fibrosis, an increase in the use of medication therapies, and an increase in the prevalence of the disease globally are some of the key drivers propelling the category’s expansion.

Figure 2: Cystic Fibrosis Market, by Treatment Method, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cystic Fibrosis Route of Administration Insights

The Cystic Fibrosis Market segmentation, based on the route of administration, includes oral and inhaled. The oral segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032 due to the simplicity and convenience of ingesting the medications. Oral drug formulations may, however, lose market share to other formulation types, such as inhalation pharmaceuticals, if new drug formulations become available that can be easily administered without the risk of invasive procedures.

Cystic Fibrosis Drug Class Insights

The Cystic Fibrosis Market data, based on drug class, includes pancreatic enzyme supplements, mucolytic, bronchodilators, antibiotics and CFTR modulators. The CFTR modulators segment dominated the cystic fibrosis market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is explained by a rise in the use of these medications to treat CF. These medications are now often used to treat CF, and other new CFTR medications are undergoing clinical studies. The primary goal of these medications is to prolong the patients' lives.

Cystic Fibrosis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America cystic fibrosis market accounted for USD 2.4 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to the rising prevalence of cystic fibrosis and the wide range of available treatments, the region made the most contribution to the study. Regional market expansion will be fueled by increased financing for research and development studies on medications for CF and other beneficial government initiatives.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: CYSTIC FIBROSIS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific cystic fibrosis market accounts for the second-largest market share. The number of patients in the area is growing as the urban lifestyle is being adopted more widely. This will likely drive the market in APAC along with rising healthcare spending. Moreover, China cystic fibrosis market held the largest market share, and the India cystic fibrosis market was the fastest growing market in the region.

Europe cystic fibrosis Market is expected to grow at the fastest CAGR from 2024 to 2032 due to a rise in the prevalence of cystic fibrosis. The market expansion in this region is further fueled by rising government support for innovation and increased funding of programs for the research and development of various CF medications. The UK contributes the most money due to the rising frequency of cystic fibrosis in this area. Further, the UK cystic fibrosis market held the largest market share, and the Germany cystic fibrosis market was the fastest growing market in the region.

Cystic Fibrosis Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the cystic fibrosis market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the cystic fibrosis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global cystic fibrosis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, cystic fibrosis industry has provided medicine with some of the most significant benefits. The cystic fibrosis market major player such as Allergan PLC, Chiesi Farmaceutici SpA, AbbVie, Hoffmann-La Roche AG, Gilead Sciences, PTC Therapeutics, Novartis AG, Vertex Pharmaceuticals Incorporated and Pharmaxis Ltd.

Roche is the brand name for F. Hoffmann-La Roche AG, a global healthcare conglomerate with two divisions: pharmaceuticals and diagnostics. Shares of Roche Holding AG, its holding company, are traded on the SIX Swiss Exchange. Basel is where the corporate headquarters are situated. In October 2020, Roche announced a collaboration with Abbie and the acquisition of the TMEM16A potentiators portfolio, both of which would be utilized to treat people with cystic fibrosis independent of their CFTR genotype as well as individuals who have other respiratory illnesses. The agreement impacts the company's capacity to increase its product offering.

Founded in 2013, the American biopharmaceutical business AbbVie is publicly traded. It began as an Abbott Laboratories spin-off. In October 2019, cystic fibrosis transmembrance conductance regulator (CFTR) potentiator chemical development was disclosed as a joint effort between AbbVie Inc. and the Cystic Fibrosis Foundation.

Key Companies in the cystic fibrosis market includes

• Allergan PLC


• Chiesi Farmaceutici SpA


• AbbVie


• Hoffmann-La Roche AG


• Gilead Sciences


• PTC Therapeutics


• Novartis AG


• Vertex Pharmaceuticals Incorporated


• Pharmaxis Ltd

Cystic Fibrosis Industry Developments

October 2020: For the treatment of patients with cystic fibrosis regardless of CFTR genotype and other respiratory disorders, Roche announced the partnership with AbbVie and the acquisition of the TMEM16A potentiators portfolio.

April 2019: The KALYDECO (ivacaftor) medication from Vertex Pharmaceuticals Incorporated has been approved by the US Food and Drug Administration (FDA) in an effort to increase the number of treatment choices for the millions of youngsters who have cystic fibrosis (CF). With the potential to alter the course of the disease, this enables doctors to start treating the underlying cause of CF in eligible infants as young as six months of age.

Cystic Fibrosis Market Segmentation

Cystic Fibrosis Treatment Method Outlook (USD Billion, 2018-2030)

• Medication


• Devices

Cystic Fibrosis Route of Administration Outlook (USD Billion, 2018-2030)

• Oral


• Inhaled

Cystic Fibrosis Drug Class Outlook (USD Billion, 2018-2030)

• Pancreatic Enzyme Supplements


• Mucolytic


• Bronchodilators


• Antibiotics


• CFTR modulators

Cystic Fibrosis Regional Outlook (USD Billion, 2018-2030)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America